Рынок наследственных заболеваний сетчатки в Северной Америке – тенденции отрасли и прогноз до 2029 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок наследственных заболеваний сетчатки в Северной Америке – тенденции отрасли и прогноз до 2029 года

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • North America
  • 350 Pages
  • Количество таблиц: 84
  • Количество рисунков: 37

>Рынок наследственных заболеваний сетчатки в Северной Америке по типу заболевания (пигментный ретинит, болезнь Штаргардта, ахроматопсия , дистрофия колбочек и палочек, хоридеремия, врожденный амавроз Лебера, отек желтого пятна и другие), по типу (диагностика и терапия), конечные пользователи (больницы, специализированные клиники, амбулаторные хирургические центры, уход на дому и другие), канал сбыта (розничные продажи и прямые торги), тенденции отрасли и прогноз до 2029 года.

Рынок наследственных заболеваний сетчатки в Северной Америке

Анализ рынка и идеи: рынок наследственных заболеваний сетчатки в Северной Америке

Наследственные заболевания сетчатки (IRD) — это группа заболеваний, которые могут привести к серьезной потере зрения или даже слепоте. Каждое IRD вызвано как минимум одним геном, который не работает должным образом. IRD могут поражать людей всех возрастов, могут прогрессировать с разной скоростью и встречаются редко. Однако многие из них являются дегенеративными, что означает, что симптомы заболевания со временем будут ухудшаться. Распространенные типы IRD включают врожденный амавроз Лебера (LCA), пигментный ретинит, хоридеремию, болезнь Штаргардта и ахроматопсию. Цель генной терапии — исправить или компенсировать дефектный ген. IRD являются особенно сильными кандидатами на лечение генной терапией из-за уникального физического строения сетчатки . По сравнению с другими органами тела глаз мал и легко доступен для введения лечения. Однако некоторые области тела являются иммунно-привилегированными, что означает, что нормальный иммунный ответ не так активен. Обычно это происходит в областях нашего тела, которые очень важны и могут быть повреждены, если возникает отек или воспаление. Это означает, что все, что имплантируется в глаз — например, клетка с исправленным геном — с меньшей вероятностью будет отторгнуто.

Диагностика и лечение наследственных заболеваний сетчатки состоят из различных методов, которые позволяют диагностировать наследственные заболевания сетчатки после одобрения продукта. Лечение заболевания недавно одобрено, что поддерживает рост рынка.

Наследственные заболевания сетчатки являются поддерживающими и направлены на замедление прогрессирования заболевания. Data Bridge Market Research анализирует, что рынок наследственных заболеваний сетчатки будет расти в среднем на 7,6% в течение прогнозируемого периода с 2022 по 2029 год.

Отчет Метрика

Подробности

Прогнозируемый период

2022-2029

Базовый год

2021

Исторические годы

2020 (Можно настроить на 2019 - 2014)

Количественные единицы

Доход в млн. долл. США, объемы в единицах, цены в долл. США

Охваченные сегменты

Тип заболевания (пигментный ретинит, болезнь Штаргардта, ахроматопсия, дистрофия колбочек и палочек, хориоидеремия, врожденный амавроз Лебера, отек желтого пятна и другие), по типу (диагностика и терапия), конечные пользователи (больницы, специализированные клиники, амбулаторные хирургические центры, домашняя медицинская помощь и другие), канал сбыта (розничные продажи и прямые торги)

Страны, охваченные

США, Канада и Мексика в Северной Америке

Охваченные участники рынка

Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson,  IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies

Inherited Retinal Diseases Market Dynamics

Drivers

  • Increase in the prevalence of Inherited Retinal Diseases

The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.

  • Increasing in Pipeline Products

As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the North America inherited retinal diseases market.High prevalence of genetic conditions

Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.

Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counselling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of  various retinal diseases will result in the expansion of inherited retinal diseases market. 

Opportunities

  • Increase in Government Initiatives Towards Inherited Retinal Disease.

Moreover, the increase in awarenss and treatment seeking rate and emerging reimbursent policies for the treatment will boost new opportunities for the market's growth rate.

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.

Restraints/Challenges

However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of inherited retinal diseases market. Additionally, lack of enough qualified professionals, and complications involved with the disease will hinder the inherited retinal diseases market growth.

This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.

Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 0.06% and 0.2%, with a North America IRD caseload in the range of 5–10 million individuals.

Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Inherited Retinal Diseases Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • In January 2022, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Diana Davis Spencer Foundation Enhanced Translational Research Acceleration Program.

Рынок наследственных заболеваний сетчатки в Северной Америке

North America Inherited Retinal Diseases Market Scope

The inherited retinal diseases market is segmented into disease type, type, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Disease Type

  • Retinitis Pigmentosa
  •  Stargardt’s Disease 
  •  Achromatopsia
  •  Cone-Rod Dystrophy
  •  Choroideremia
  •  Leber Congenital Amaurosis (LCA)  
  •  Macular Edema
  •  Others

On the basis of type, the inherited retinal diseases market is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others

Type

  • Diagnosis
  • Therapy

On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory surgical center
  • Home Healthcare
  • Others

On the basis of end-users, the inherited retinal diseases market is segmented into hospitals, specialty clinics, ambulatory surgical center, home healthcare and others

Distribution Channel

  • Retail Sales
  • Direct Tender

The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.

Pipeline Analysis

The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.

Inherited Retinal Diseases Market Regional Analysis/Insights

The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.

The countries covered in the inherited retinal diseases market report are U.S., Canada and Mexico in North America.

U.S. dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Inherited Retinal Diseases Market Share Analysis

The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.

Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson,  IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.

Research Methodology: North America Inherited Retinal Diseases Market

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Рыночные данные анализируются и оцениваются с использованием рыночных статистических и когерентных моделей. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в рыночном отчете. Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Помимо этого, модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, анализ доли рынка компании, стандарты измерения, анализ Северной Америки и регионов и доли поставщиков. Пожалуйста, запросите звонок аналитика в случае дальнейшего запроса.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA INHERITED RETINAL DISEASES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS FOR NORTH AMERICA INHERITED RETINAL DISEASES MARKET

5 REGULATORY FRAMEWORK

6 PREMIUM INSIGHTS

6.1 PESTEL ANALYSIS

6.2 POTER’S FIVE FORCES MODEL

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES

7.1.2 INCREASE IN PIPELINE PRODUCTS

7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES

7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER

7.2 RESTRAINTS

7.2.1 HIGH COST OF TREATMENT AND PROCEDURES

7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS

7.3 OPPORTUNITIES

7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)

7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE

7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT

7.4 CHALLENGES

7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY

7.4.2 LIMITED ACCESS TO TREATMENT

8 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 RETINITIS PIGMENTOSA

8.3 STARGARDT’S DISEASE

8.4 ACHROMATOPSIA

8.5 CONE-ROD DYSTROPHY

8.6 CHOROIDEREMIA

8.7 LEBER CONGENITAL AMAUROSIS (LCA)

8.8 MACULAR EDEMA

8.9 OTHERS

9 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY TYPE

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 CLINICAL DIAGNOSIS

9.2.1.1 RETINAL IMAGING

9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)

9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)

9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)

9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING

9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING

9.2.1.2 ELECTROPHYSIOLOGICAL TESTS

9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)

9.2.1.2.2 DARK ADAPTOMETRY (DA)

9.2.1.3 VISUAL FIELD TEST

9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS

9.2.1.3.2 MANUAL FIELD TEST

9.2.1.4 CLINICAL EYE EXAMINATION

9.2.1.4.1 SLIT LAMP

9.2.1.4.2 INDIRECT OPHTHALMOSCOPY

9.2.1.4.3 REFRACTION TEST

9.2.1.4.4 DILATION EXAM

9.2.1.5 OTHERS

9.2.2 GENETIC DIAGNOSIS

9.3 THERAPY

9.3.1 GENE THERAPY

9.3.2 RETINAL PROSTHETIC

9.3.3 NEUROPROTECTIVE AGENTS

9.3.3.1 VITAMIN A PALMITATE

9.3.3.2 DOCOSAHEXAENOIC ACID

9.3.3.3 LUTEIN

9.3.3.4 OTHERS

9.3.4 OTHERS

10 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 SPECIALTY CLINICS

10.4 AMBULATORY SURGICAL CENTERS

10.5 HOME HEALTHCARE

10.6 OTHERS

11 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 RETAIL SALES

11.2.1 HOSPITAL PHARMACIES

11.2.2 RETAIL PHARMACIES

11.2.3 OTHERS

11.3 DIRECT TENDER

12 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY REGION

12.1 NORTH AMERICA

12.1.1 U.S.

12.1.2 CANADA

12.1.3 MEXICO

13 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 SPARK THERAPEUTICS, INC.

15.1.1 COMPANY SNAPSHOT

15.1.2 COMPANY SHARE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENTS

15.1.4.1 PROGRAM LAUNCH

15.1.4.2 ACQUISITIONS

15.2 NOVARTIS AG

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.2.5.1 AGREEMENT

15.3 OKUVISION

15.3.1 COMPANY SNAPSHOT

15.3.2 COMPANY SHARE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENTS

15.3.4.1 EXPANSION

15.3.4.2 EVENTS

15.3.4.3 APPROVAL

15.4 NIDEK CO., LTD

15.4.1 COMPANY SNAPSHOT

15.4.2 COMPANY SHARE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENTS

15.4.4.1 PRODUCT LAUNCH

15.4.4.2 PRODUCT LAUNCH

15.5 INVITAE CORPORATION

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENTS

15.5.5.1 PROGRAM LAUNCH

15.5.5.2 ACQUISITION

15.6 ZEISS INTERNATIONAL

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENTS

15.6.4.1 EVENTS

15.6.4.2 SOCIAL INVOLVEMENT

15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENTS

15.8 NEUROSOFT

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 ASTELLAS PHARMA INC.

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 BIONIC VISION TECHNOLOGIES

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.10.3.1 AWARD

15.11 COAVE THERAPEUTICS

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.11.3.1 AGREEMENT

15.12 GENSIGHT BIOLOGICS

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.12.4.1 EVENT

15.12.4.2 AWARD

15.13 IONIS PHARMACEUTICALS

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENT

15.13.4.1 EVENT

15.14 IVERIC BIO

15.14.1 COMPANY SNAPSHOT

15.14.2 PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENTS

15.15 JOHNSON &JOHNSON SERVICES, INC.

15.15.1 COMPANY SNAPSHOT

15.15.2 REVENUE ANALYSIS

15.15.3 PRODUCT PORTFOLIO

15.15.4 RECENT DEVELOPMENT

15.15.4.1 COLLABORATION

15.16 LKC TECHNOLOGIES, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.16.3.1 PRODUCT LAUNCH

15.17 MEIRAGTX LIMITED

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENTS

15.17.3.1 EVENTS

15.17.3.2 AWARD

15.17.3.3 COLLABORATION

15.18 OCUGEN INC.

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENTS

15.18.3.1 INVESTMENT

15.18.3.2 CLINICAL TRIAL

15.19 PIXIUM VISION

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENT

15.19.4.1 AWARD

15.2 PROQR THERAPEUTICS

15.20.1 COMPANY SNAPSHOT

15.20.2 PRODUCT PORTFOLIO

15.20.3 RECENT DEVELOPMENT

15.20.3.1 EVENT

15.21 SECOND SIGHT

15.21.1 COMPANY SNAPSHOT

15.21.2 PRODUCT PORTFOLIO

15.21.3 RECENT DEVELOPMENT

15.21.3.1 PRODUCT LAUNCH

15.22 SPARING VISION

15.22.1 COMPANY SNAPSHOT

15.22.2 PRODUCT PORTFOLIO

15.22.3 RECENT DEVELOPMENT

15.22.3.1 ACQUISITION

15.23 REGENXBIO INC.

15.23.1 COMPANY SNAPSHOT

15.23.2 PRODUCT PORTFOLIO

15.23.3 RECENT DEVELOPMENTS

15.23.3.1 EVENT

15.23.3.2 COLLABORATION

15.23.3.3 CERTIFICATION

15.24 RENEURON GROUP PLC

15.24.1 COMPANY SNAPSHOT

15.24.2 PRODUCT PORTFOLIO

15.24.3 RECENT DEVELOPMENT

15.24.3.1 STRATEGIC INITIATIVE

16 QUESTIONNAIRE

17 RELATED REPORTS

Список таблиц

TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:

TABLE 2 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 46 U.S. INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 47 U.S. INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 U.S. THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 U.S. NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 U.S. DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 U.S. CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 U.S. RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 U.S. ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 U.S. VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 U.S. CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 U.S. INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 57 U.S. INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 58 U.S. RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 CANADA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 60 CANADA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 CANADA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 CANADA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 CANADA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CANADA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 CANADA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 CANADA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 CANADA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 CANADA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 CANADA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 CANADA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 CANADA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 MEXICO INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 73 MEXICO INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 MEXICO THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 MEXICO NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 MEXICO DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 MEXICO CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 MEXICO RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 MEXICO ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 MEXICO VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 MEXICO CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 MEXICO INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 MEXICO INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 MEXICO RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

Список рисунков

FIGURE 1 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN NORTH AMERICA INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE NORTH AMERICA INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INHERITED RETINAL DISEASES MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA INHERITED RETINAL DISEASES MARKET

FIGURE 16 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021

FIGURE 17 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)

FIGURE 18 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021

FIGURE 21 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 22 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 23 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, 2021

FIGURE 25 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 26 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)

FIGURE 27 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE

FIGURE 28 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 29 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 30 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 31 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 32 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)

FIGURE 33 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)

FIGURE 34 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 35 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 36 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 37 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The North America Inherited Retinal Diseases Market will be projected to grow at a CAGR of 7.6% during the forecast period of 2022 to 2029.
Increase in the prevalence of Inherited Retinal Diseases, and Increasing in Pipeline Products are the significant factors flourishing the growth of the North America Inherited Retinal Diseases Market.
Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies are the major players operating in the North America Inherited Retinal Diseases Market.
The high cost associated with the available treatment and lack of infrastructure in low-income countries are poised to restrict the North America Inherited Retinal Diseases Market growth.